| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 119.22 | 2.5% | 24.1% |
| Total Income | 119.22 | 2.5% | 24.1% |
| Expenditure | 60.81 | 3.0% | 7.2% |
| PBT | 66.08 | 7.5% | 41.3% |
| Net Profit | 54.77 | 2.1% | 42.9% |
| OPM | 49.00% | 2.86pp | 8.07pp |
| NPM | 45.94% | 2.13pp | 6.03pp |
| EPS | 1.85 | 3.1% | 39.1% |
Krystal Biotech Announces Q2 2026 Financial Results with $119.2M VYJUVEK Revenue
03 Aug 2026 · 3 Aug, 4:37 pm
Summary
Krystal Biotech announced its second quarter 2026 financial results, reporting $119.2 million in global VYJUVEK net product revenue, a 24% increase year-over-year, with a strong gross margin of 95%. The company highlighted robust US market performance with over 730 reimbursement approvals and an expanding prescriber base, alongside growing momentum in international markets. Krystal Biotech ended the quarter with $1.1 billion in cash and investments and reported a net income of $54.8 million, or $1.79 per diluted share. Management expressed optimism about the company's transition to a multi-product genetic medicines company, with multiple clinical data readouts and expected launches in Spain and Italy by year-end.
Key Highlights
- 1
Krystal Biotech reported $119.2 million in global VYJUVEK net product revenue for the second quarter of 2026, an increase of 24% compared to the prior year second quarter.
- 2
The company achieved a gross margin of 95% for VYJUVEK in the second quarter.
- 3
VYJUVEK has secured over 730 reimbursement approvals and expanded its prescriber base to over 640 unique prescribers in the United States by the end of Q2 2026.
- 4
The company is on track for VYJUVEK commercial launches in Spain and Italy before the end of 2026.
- 5
Krystal Biotech ended the second quarter with a strong balance sheet, holding $1.1 billion in cash and investments.
- 6
Net income for the second quarter of 2026 was $54.8 million, or $1.79 per diluted common share.
- 7
The company expects multiple additional marketing authorization applications for VYJUVEK to be filed in the second half of 2026, including in Switzerland and Australia.
Management Comments
Krish S. Krishnan
Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts. VYJUVEK is not only changing the standard of care for DEB patients around the world, it is also giving us the ability to advance high-conviction rare disease programs across the eye, lung, and skin with focus and discipline. We believe the next 12 to 18 months have the potential to mark an important transition for Krystal from a commercial success story to a multi-product genetic medicines company.
Informational and educational content only. Not investment advice.